Claris Ventures

📣 Honored to welcome Dr. Adi Hoess to ALKemist Bio Board of Directors

📣 Kudos to our portfolio company NeoPhore Ltd, that just announced the appointment of Michael Shih as Chief Executive Officer. 💊 Michael Shih has nearly 20 years of experience in business development, licensing and mergers & acquisitions and was most recently Vice President of Corporate Development at Kite Pharma, where he led multiple business development opportunities for the company. We can't be happier to see the team growing, as we progress our first-in-class approach based on DNA-MMR inhibition in #cancer. Here the full press release: https://lnkd.in/dv5d2rD9

📣 Paramount update from our porfolio company Resalis Therapeutics, announcing today a strategic equity investment from Sanofi to accelerate the development of its lead investigational candidate, RES-010, through a Phase 2 proof-of-concept clinical trial 👏 Big ups to the CEO Alessandro Toniolo, to Riccardo Panella, Sakari Kauppinen and the whole team - and to our co-investors Sunstone Life Science Ventures, IAG and Club degli Investitori Upwards and onwards 🚀 #biotech #pharma #vc #strategicinvestment #obesity

🧪 FENS Forum 2024 was incredible! Hundreds of speakers and thousands of participants from around the world gathered in #Vienna to share breakthrough advancements in CNS research 🧠 It was an amazing opportunity to explore emerging trends in neuroscience, be surrounded by top researchers, and connect with some of our founders! #FENS2024 #Biotech #Neuroscience #venturecapital

🌟 Exciting News Alert! 🌟 We're thrilled to share the groundbreaking partnership between one of our portfolio companies, Sibylla Biotech , and The University of Texas MD Anderson Cancer Center. Together, they're embarking on a pioneering journey to develop novel small-molecule cancer therapies known as Folding Interfering Degraders (FIDs). #CancerResearch #Partnership #Sibylla #MDAnderson #FoldTheFuture

📣 The pharmaceutical company Bristol Myers Squibb (NYSE: MBY) just announced its investment in our portfolio company NeoPhore Ltd - and we couldn't be happier! 💊 NeoPhore unique approach could offer therapeutic opportunities to patients suffering from solid cancers not eligible to immune check-point inhibitors, a possible paradigm shift in immune-oncology. Bristol Myers Squibb investment is a testament to the relevance and uniqueness of NeoPhore science, originated from Prof. Alberto Bardelli's lab. Kudos to the whole team, upwards and onwards! #biotech #venturecapital #pharma #investmnet #deal

🎉Welcome Chiara Donini, PhD to Claris Ventures!🎉 We are thrilled to announce Chiara as our new Senior Analyst! 🌟 Chiara brings over 5 years of post-doctoral experience in immuno-oncology and cell therapy. She holds a PhD in Complex Systems for Life Sciences from the University of Turin and advanced studies in Pharma Management from Alma Laboris Business School. Her roles have included developing CAR-cell therapy strategies at San Luigi Gonzaga Hospital and working in technology transfer at Bioindustry Park Silvano Fumero. Chiara's expertise and proactive approach make her a valuable addition to our team. Join us in welcoming her to Claris Ventures! #Welcome #ClarisVentures #LifeSciences #Biotechnology #NewTeamMember #VentureCapital

🙌 Congratulations to our portfolio company Sibylla Biotech for the strategic collaboration closed with ONO PHARMACEUTICAL CO., LTD., announced today! The value and standing of this deal crystallizes Sibylla’s leading position at the edge of #drug #discovery, leveraging on its unique and proprietary technology based on Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) 🧫🧫🧫 We look forward to the exciting future progress and achievements that Lidia Pieri, Giovanni Spagnolli and the whole team will pursue, fully committed from our side to supporting this great company along the way! 🚀 Full press release here: https://lnkd.in/eH3SRg2A #Italianbiotech #venturecapital #drugdiscovery #deal

🚀 Exciting News in Biotech Collaboration! 🧬 Thrilled to announce a strategic partnership between Claris Ventures and Evotec to accelerate programs from Claris’s portfolio into the clinic seamlessly. 🌐 Claris's portfolio, comprising nine biotech companies across Italy, Switzerland, and the UK, will now have streamlined access to Evotec’s full pre-clinical and clinical development capabilities. This collaboration builds on the success with IAMA Therapeutics, where Evotec supported their lead program IAMA-6 from pre-clinical to a successful Clinical Trial Application in December 2023. 📈 The acceleration framework agreement extends this streamlined access to all Claris's portfolio companies, providing them with Evotec’s integrated services. Evotec will continue to support the progress of these programs through a robust governance model. 🔗 Read more about our commitment to innovation and delivering impactful solutions in the press release: https://lnkd.in/eaAynVxp #Biotech #VentureCapital #Innovation #Collaboration #Biopharma #ClinicalDevelopment #Partnership

🚀 We are thrilled to announce the addition of new partners to the NeoPhore Ltd family: NEVA SGR, LIFTT and Simon Fiduciaria SpA (the fiduciary company of Ersel Banca Privata Group) have participated in the latest financing round (£9.6m) to support the development of NeoPhore's preclinical compounds active in the #immunooncology space. Their commitment underscores the confidence in NeoPhore's mission to revolutionize cancer treatment through an innovative mechanism of action that induces #neoantigen expression eliciting #immunogenicity in solid tumors. A special thanks to our existing syndicate, CPF managed by SIXTH ELEMENT CAPITAL LLP, 3B Future Health Fund I & II, Astellas Pharma Venture Management, 2invest, Club degli Investitori and IAG for their steady support. Together, we are working towards enhancing clinical outcomes and reshaping the landscape of cancer treatment. 💊 #neoantigen #mismatchrepair #cancerresearch